On the other hand, activation of TLR9 is a potential therapeutic strategy against SLE with recent studies highlighting TLR9 deletion culminating to the augmentation of lymphocyte and plasmacytoid DC, which is accompanied by elevation of IgG and IFN-α serum [149]. The gene discussed is TLR9; the disease is systemic lupus erythematosus.